We used pharmacokinetic (PK) targeting of BU in 145 consecutive patients treated with fludarabine and i.v. BU. BU was given once daily at 130 mg/m 2 per day on days 1 and 2; doses for days 3 and 4 were adjusted in 92 patients (63%) to an average daily area under the concentration-time curve (AUC) of 5300 lM/min. In the remaining 53 patients, the first-dose AUC was within the target range and no dosing adjustments were required. First-dose AUC, maximum concentration and clearance were not correlated with age, race, ethnicity, performance status, or hematopoietic cell transplant comorbidity index. Women had higher clearance than men (median 2.9 vs 2.5 mL/min/kg; P ¼ 0.001). BU toxicities were not associated with first-dose AUC or any other PK parameter measured. First-dose BU AUC was not associated with non-relapse mortality (NRM) or survival, but higher AUC was predictive of relapse. We did not find an increased risk of toxicity or NRM in patients with high first-dose AUC presumably because of the dose adjustment. We conclude that PK targeting of BU as described here provides a simple, safe and effective method of delivering high BU doses before transplantation in a wide variety of patients.
Introduction
In many pretransplant conditioning regimens, fludarabine has replaced CY to provide immunosuppression with lower toxicity, and when administered just before BU (fludarabine and i.v. BU), the combination has been shown to be safe and effective in a wide variety of patient populations. [1] [2] [3] [4] Systemic BU exposures as measured by steady state concentrations or area under the plasma concentrationtime curve (AUC) have been correlated both to increased risk of toxicity and mortality, [5] [6] [7] [8] and graft rejection or disease relapse. 9 These studies suggest a pharmacodynamic relationship between BU systemic exposure and outcomes. As a result, pharmacokinetic (PK) targeting of BU is being used routinely to achieve a desired systemic exposure. Although i.v. BU has overcome unpredictable oral bioavailability, 10 significant interpatient variation remains and patients receiving i.v. BU dosed on weight or body surface area continue to be at risk for toxicity and lack of efficacy, because of over-and underexposure, respectively. More precise BU systemic exposure with PK-based dose adjustment may lead to improved outcomes. 11 Beginning in July of 2004, we adopted fludarabine and once daily i.v. BU as our standard conditioning regimen for patients undergoing allogeneic HCT. We optimized BU dosing by PK targeting to an average daily AUC of 5300 mM/min. This AUC was chosen as it corresponds to a concentration at a steady state of 900 ng/mL, previously determined to have low non-relapse mortality (NRM) when oral BU was evaluated in combination with fludarabine. 2 We report here multivariable models for NRM, relapse, survival and disease-free survival.
Patients and methods

Patients
This retrospective study with waiver of consent was reviewed and approved by the University of South Florida Institutional Review Board. Patients receiving fludarabine and i.v. BU as standard conditioning for allogeneic HCT from July 2004 to February 2007 were screened for inclusion and included if their BU dose was targeted to an AUC of 5300 mM/min. Disease status was categorized as standard risk (acute leukemia in first CR or CML in first chronic phase) or high risk (all others). Hematopoietic cell transplant comorbidity index was assessed retrospectively according to Sorror et al. 12 with the exception of the pulmonary score, which was based only on forced expiratory volume and not carbon monoxide diffusion capacity measurements. 13 
Donors
All donors had high-resolution molecular typing for HLA-DRB1 and -DQB1. Unrelated donors had sequence-based typing for HLA-A, -B and -C, whereas sibling donors had low-intermediate resolution molecular typing of HLA-A, -B and -C. All patients were to receive unmanipulated G-CSF mobilized peripheral blood hematopoietic cells.
Regimen and BU PK analysis Fludarabine (Fludara Bayer HealthCare; Wayne, NJ, USA) 40 mg/m 2 was given i.v. once daily for 4 days, with each infusion followed immediately once daily by i.v. BU (Busulfex Otsuka America Pharmaceutical; Rockville, MD, USA). Hematopoietic cells were infused at least 36 h after the end of the last BU infusion. The dose of BU for days 1 and 2 was 130 mg/m 2 per day given over 3 h. Blood samples were drawn at 15 min after the end of the BU infusion then at 2, 4, 6 and 9 h after the start of the infusion. Samples were drawn from the patients' central venous catheter from a lumen other than the lumen being used for BU infusion. Before withdrawing the sample, standard flushing procedures were performed and 10 mL of blood was withdrawn and discarded. Plasma was prepared, frozen, shipped overnight to the Hospital of the University of Pennsylvania Clinical Toxicology Laboratory where PK analyses were performed. Samples were analyzed using gas chromatography/mass spectrometry with selected ion monitoring. 14 The initial BU steady-state AUC was estimated from concentration data using the single compartment first order elimination model for i.v. infusion using WinNonlin, v4.1 in compliance with the company's 'Acceptable Use Policy', (Pharsight Corp., Mountain View, CA, USA). BU doses for days 3 and 4 were adjusted based on a linear relationship between dose and AUC to achieve an average daily AUC of 5300 mM/min over the 4 days of administration. Adjustments were made if the first-dose AUC was 410% below or above the target (that is, o4770 or 45830 mmol/min/L). Repeat levels were not obtained as dosing adjustment methods had been validated in an ongoing prospective clinical trial at this institution (ClinicalTrials.gov Identifier: NCT00361140).
Patients with mismatched unrelated donor grafts were given rabbit anti-thymocyte globulin (rATG; Thymoglobulin Genzyme Corporation, Cambridge, MA, USA) 1 mg/kg i.v. on day À3 followed by 3.25 mg/kg per day on day À2 and day À1. Two patients received alemtuzumab (Campath Genzyme Corporation, Cambridge, MA, USA) as part of the conditioning to prevent rejection. Seven patients with B-cell lymphoid malignancies were given rituximab (Rituxan Genentech Inc., San Francisco, CA, USA) 375 mg/m 2 i.v. on day 1 and day 8 after transplant.
Supportive care
The first 26 patients received phenytoin for seizure prophylaxis; lorazepam was used in subsequent patients. Ursodiol was given to prevent hepatotoxicity. Neutrophil engraftment was defined as the first day that the ANC was 40.5 Â 10 9 /L on 3 consecutive days. Platelet engraftment was defined as the first day 420 Â 10 9 /L on 3 consecutive days without transfusion for at least 7 days.
Chimerism studies were done using a PCR/short tandem repeat method on unsorted BM samples. In addition, some patients had peripheral blood CD3/CD33 subsets isolated by fluorescence-activated cell sorting and subsequently analyzed for donor chimerism. 16 Acute GVHD was graded up to day 100 after transplant using consensus criteria. 17 Chronic GVHD was graded as mild, moderate or severe based on the National Institutes of Health Consensus Development Project. 18 Patients were censored for the assessment of GVHD at the time of relapse or NRM from causes other than GVHD.
Statistical analysis
Categorical and continuous variables are summarized as frequencies or percentages and as the median and range, respectively. First-dose AUC was first analyzed as a continuous variable then categorized as o4770 mM/min (410% below target), 4770-5830 (±10% of target) and 45830 (410% above target). Correlation between the two continuous variables was evaluated by Spearman's correlation coefficient. Differences in the medians for continuous variables were assessed by Wilcoxon's rank-sum test. OS and relapse-free survival (RFS) were estimated from date of transplant using the Kaplan-Meier method. Survival curves among subgroups were compared using the log-rank test. Cumulative incidences of acute and chronic GVHD, relapse and NRM were generated based on the life-table method and compared using the method of Gray. 19 The 95% confidence intervals for cumulative incidence point estimates were driven based on the ln (-ln) transformation. 20 For OS and RFS, the relationship between these outcomes and all variables was examined first using univariable analysis. Cox proportional hazard Pharmacokinetic targeting of BU J Perkins et al modeling was then used with variables as covariates. For cumulative incidence outcomes, a subdistribution hazards regression model by the method of Fine and Gray was utilized for univariable and multivariable analysis. 21 Those variables with P-value of 0.2 or less in univariable analysis were selected for construction of the multivariable model. The backward selection procedure with a P-out value of 0.1 was utilized.
Results
BU administration and PKs
Patient, donor and treatment characteristics are summarized in Table 1 . PK parameters obtained in this population (Table 2 ) are similar to those that have been previously reported in patients receiving i.v. BU on a similar schedule. 22 A total of 15% of patients required decreased third and fourth doses whereas 48% required an increase in those doses; a threefold difference in total dose was required to achieve an average AUC of 5300 mM/min. The remaining patients did not require dose adjustments as their first-dose AUC fell within the target range.
First-dose BU AUC, maximum concentration and clearance were not correlated with age, race, or ethnicity; women had significantly higher clearance than men (median 2.9 vs 2.5 mL/min/kg; P ¼ 0.001). First-dose BU AUC was negatively correlated with total BU dose (r ¼ À0.92; Po0.01) because of the increased dose given in response to a low AUC. As expected, first-dose BU AUC was positively correlated with first dose maximum concentration (r ¼ 0.67; Po0.01) and negatively correlated with first-dose clearance (r ¼ À0.85; Po0.01). First-dose BU AUC was weakly correlated with Karnofsky performance status (r ¼ À0.15; P ¼ 0.07), but not with hematopoietic cell transplant comorbidity index.
Toxicity
The median duration of hospitalization during the first 100 days after transplant was 24 (range 14-85) days and was not correlated with first-dose BU AUC. No patient suffered a seizure attributable to BU. In the first 100 days after transplant, 15 (10%) patients had grade 3 (11 patients) or 4 (4 patients) elevations in serum hepatic transaminases or serum bilirubin; 3 of these patients had veno-occlusive disease/sinusoidal obstructive syndrome per the McDonald criteria. 15 The elevations were reversible in all cases. Three other cases of veno-occlusive disease/sinusoidal obstructive syndrome occurred for a total of six (4%): two mild and four moderate. All veno-occlusive disease/sinusoidal obstructive syndrome cases resolved with supportive care only. Four patients (3%) developed interstitial pneumonitis in the absence of an infectious etiology. One patient did not require therapy; two patients responded to glucocorticoids and one expired. None of the toxicities were correlated with any of the PK parameters analyzed.
Engraftment and GVHD
Primary engraftment occurred in all, but one patient. A second patient had delayed graft failure. These two cases (1.5%) were not associated with a low BU AUC. The median time to neutrophil recovery to an ANC 4500 Â 10 6 /L was 16 days (10-56 þ ) and to platelet 420 Â 10 9 /L was 16 days (9-110 þ ). Chimerism results are given in Table 3 . There was no correlation between firstdose BU AUC and BM or lymphocyte chimerism studies around day 30 or day 100 after transplant. The cumulative incidence of grades 2-4 and grades 3-4 acute GVHD were 76 and 21%, respectively. 59% of patients had either moderate or severe chronic GVHD at 2 years after transplant. There was no relation between first-dose BU AUC and acute or chronic GVHD incidence or severity.
NRM and relapse
NRM at 100 day and 1 year for all patients was 6% (95% CI 3-11%) and 21% (95% CI 15-28%), respectively ( Figure 1 ). There were no significant differences in NRM when the patients were divided by first-dose BU AUC, disease risk, age, comorbidity index or performance status. Results of univariable and multivariable analyses are shown in Supplementary Table 4 . In multivariable analyses, having an unrelated donor and a diagnosis of CML or lymphoma were associated with increased NRM. Age, hematopoietic cell transplant comorbidity index, Karnofsky performance status, disease risk, CMV serologic status and first-dose BU AUC (either as a continuous or categorical variable) were not independently predictive of NRM.
The cumulative incidence of relapse is shown in Figure 2 and results of univariable and multivariable analyses are in Supplementary Table 5 . There was no significant differences seen when patients were categorized by diagnosis, age, comorbidity index or performance status. Disease risk was marginally associated with relapse. Having a mismatched MUD transplant appeared to offer some protection against relapse, but not independently so. First-dose BU AUC 410% of the target (45830 mM/min) was a significant predictor of a higher incidence of relapse in the multivariable analysis. When evaluated as a continuous variable, increasing first-dose AUC was also significantly associated with an increased rate of relapse (data not shown).
Overall and RFS
Causes of death are given in Supplementary Table 6 . Univariable and multivariable analyses for overall and RFS are shown in Supplementary Tables 7 and 8 , respectively. Only disease risk was a significant independent predictor of overall and RFS. First-dose BU AUC was not a significant covariate, when evaluated either as a continuous or categorical variable. Kaplan-Meier estimates of OS at 2 years for standard vs high risk patients were 61 vs 39% (P ¼ 0.04), respectively; the corresponding values for RFS were 57 vs 32% (P ¼ 0.02) (Figure 3 ) First-dose BU AUC, age, donor match, hematopoietic cell transplant comorbidity index scores and Karnofsky performance status were not independently predictive of either overall or RFS.
Discussion
The combination of fludarabine and BU is a commonly used conditioning regimen because of its lower risk of NRM compared with other more intensive regimens. We adopted this regimen with PK BU targeting and have retrospectively reviewed outcomes to evaluate the effect of the targeting strategy. One potential limitation of our approach is the absence of confirmation of the accuracy of dose adjustments that were made based on first-dose BU PK parameters. However, several investigators have shown the consistency of these parameters throughout the dosing regimen when the i.v. form of BU is used, such that differences between the actual and the predicted systemic exposures were not significant 1, 3, 8, 22, 23 In addition, as mentioned in the Patients and methods section, we have validated the accuracy of dose adjustment at our institution in an ongoing prospective trial. On the basis of this information, we did not feel it necessary to repeat PK analysis after subsequent doses.
We saw no correlation between the development of toxicities, traditionally attributed to BU, and any of the PK parameters evaluated. In another report analyzing the relationship between BU PKs and toxicity, Andersson, et al. 8 showed a strong correlation between BU systemic exposure and hepatotoxicity, as well as acute GVHD and gastrointestinal toxicity. The difference in their results compared with ours may be because 25 of the 36 patients did not have their doses adjusted to a specific target and may have been exposed to higher levels of BU over the entire BU dosing period, placing them at an increased risk for toxicity, unlike our population in whom those with a first-dose AUC above the target were subsequently doseadjusted. The difference may also be because of the difference in conditioning regimen (use of CY vs fludarabine). The potential contribution of CY to the hepatotoxicity of BU is well known [24] [25] [26] and the replacement of 100 (57-100) 100 (10-100) 100 (92-100) 100 (100-100)
Pharmacokinetic targeting of BU J Perkins et al CY with fludarabine has, in general, resulted in a lower incidence of this toxicity. In addition, our patients received ursodiol, which may have protective effects with respect to hepatotoxicity. Several reports of adult patients demonstrate a significant relationship between BU exposure (as measured by a single dose AUC or average steady-state concentration, without dose adjustment) and survival outcomes. 6, 8, 9, 23 In the only report using a regimen similar to ours, Geddes et al. 23 treated 130 patients with i.v. BU (a fixed dose of 3.2 mg/kg per day for 4 days) and fludarabine (50 mg/m 2 per day for 5 days). BU levels were measured after the third dose on all patients; first-dose PK studies were also done on eight consecutive patients to ensure consistency in AUC between doses. The 16 patients with an AUC over 6000 mM/min had a significantly higher NRM at 100 days than those with lower AUCs (19 vs 6%; P ¼ 0.002), which translated into a lower overall and PFS. There were no significant differences between the patients with AUC 46000 and those with AUC o6000 with respect to engraftment, regimen-related toxicities, GVHD, or relapse.
The investigators concluded that their data supported a role for therapeutic drug monitoring with dose adjustment of BU to avoid high systemic exposures. Our data also support this conclusion as high first-dose BU AUC was not an independent risk factor for NRM, overall or RFS presumably because of the dose adjustment used to maintain the targeted AUC over the entire dosing interval. Our findings are also consistent with others who have used PK dose adjustments BU when given in combination with CY and did not report a relationship between first-dose BU exposure and after transplant outcomes. 27 Although these data suggest the superiority of targeted BU dosing over a fixed dose regimen, a prospective controlled clinical trial would be necessary to draw definitive conclusions.
Another finding of interest is the lack of independent effect of traditional pretransplant risk factors, such as age (especially 460 years), comorbidity index score and performance status on after transplant outcomes. Several reports have shown the importance of these characteristics and others as predictors of survival. 12, [28] [29] [30] [31] Although it is not entirely clear as to why they were not significant in our cohort, one possibility is that by targeting BU exposures, the mechanism by which these factors influence mortality is mitigated. In addition, this was a retrospective study that lacked sufficient power to demonstrate a significant correlation between these factors and outcomes.
Donor source was predictive of NRM and relapse with receipt of a mismatched unrelated donor allograft conferring the highest risk of NRM and the lowest risk of relapse. This may in part be due to the higher incidence of acute GVHD traditionally seen in these patients. The negative effect of unrelated donor allografts on NRM was counterbalanced by the positive effect on relapse and therefore this factor was non-contributory as a predictor for survival outcomes. One unexpected finding was that high first-dose BU AUC was a negative predictor for relapse. The reason for this is not clear and the finding may be an artifact given the small number of patients having a first-dose AUC of 46000. Potentially, this could have been caused by a lower total dose of BU given after dose adjustment for the high first-dose AUC. However, doses were adjusted to an average AUC over the 4 days of BU administration so that even though total doses were lower, systemic exposures would have been similar. Previous reports have shown that systemic exposure is important in predicting outcome, not dose. Further work with a larger sample size will need to be done to validate and explain this finding before a definitive statement can be made with respect to its significance.
We found that dose adjustment based on PK monitoring may reduce the risks associated with suboptimal or potentially toxic levels of BU when used in combination with fludarabine. Arguably, 37% of patients did not require dosing adjustments in order to achieve the targeted exposure chosen in this population, suggesting that many patients receiving i.v. BU would not benefit from PK-based dosing interventions. Also, much of the literature documenting the relationships between BU systemic exposure and adverse outcomes comes from oral BU regimens and/ or those containing CY. Different paradigms might exist for i.v. BU in different drug combinations where the ideal level of BU systemic exposure has not been clearly defined. Although not seen in our sample of patients, this 'therapeutic window' may also depend on patient-related factors, such as age, performance status, diagnosis, disease risk and so on. That being said, a majority of our patients reported here did require dosing adjustments and the regimen was very well tolerated. In addition, older patients, those with comorbidities or reduced functional status did not appear to be at increased risk for reduced survival. Whether or not the tolerability of the regimen in these patients was enhanced by PK-targeted dosing can only be addressed in a comparative manner. In the meantime, these results suggest that PK targeting of BU as described here provides a simple, safe and effective method of delivering high BU doses before transplantation in a wide variety of patients. 
